

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

**PHASE II CLINICAL TRIAL OF MT200605 FOR ACUTE ISCHEMIC
STROKE (AIS) COMPLETED DATABASE LOCK**

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Phase II clinical trial of the Group’s independently developed drug candidate MT200605 for the treatment of AIS has completed database lock.

MT200605 is an injectable neuroprotective agent with a dual synergistic mechanism of action. By simultaneously activating the TrkB receptor and scavenging oxygen free radicals, it is designed, on the one hand, to inhibit neuronal apoptosis, reduce excitotoxicity and attenuate inflammatory responses, thereby reducing cell death, and, on the other hand, to improve synaptic plasticity and promote neuronal regeneration through upstream reactivation of the endogenous repair program in neuronal cells.

The Phase II clinical trial of MT200605 for AIS conducted in China is a multi-center, randomized, double-blind and placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of MT200605. This Phase II clinical trial enrolled its first patient in September 2025, completed enrollment of all 360 patients in March 2026, reached last patient out in June 2026, and has recently completed database lock.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 24 July 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.